Central and mixed sleep apnea related to patients treated with maxillomandibular advancement for obstructive sleep apnea: A retrospective cohort study.
Central sleep apnea
Maxillomandibular advancement
Mixed sleep apnea
Obstructive sleep apnea
Treatment emergent central sleep apnea
Upper airway surgery
Journal
Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
ISSN: 1878-4119
Titre abrégé: J Craniomaxillofac Surg
Pays: Scotland
ID NLM: 8704309
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
06
08
2021
revised:
03
06
2022
accepted:
14
06
2022
pubmed:
2
7
2022
medline:
4
8
2022
entrez:
1
7
2022
Statut:
ppublish
Résumé
The aim of this study was to evaluate the clinical efficacy of maxillomandibular advancement (MMA) for obstructive sleep apnea (OSA) patients with a percentage of central and mixed apnea index in the total apnea-hypopnea index (CMAI%) ≧25%. Patients treated with MMA for OSA were retrospectively evaluated for baseline and postoperative patient data and polysomnographic results. The pre- and postoperative obstructive, central and mixed apnea parameters were compared. Of the included 78 patients, 21 patients (27%) presented with CMAI% ≧25% (median CMAI%, 49.1%; 35.9-63.8) prior to MMA. In 67% of these cases, MMA resulted in CMAI% <25 (median CMAI%, 6.1%; 2.1-8.9) and significantly improved the apnea-hypopnea index (AHI) (p < 0.001), the lowest oxyhemoglobin saturation (p < 0.001), central and mixed apnea index (p < 0.001), percentage of central and mixed apneas of total AHI (p = 0.004), central apnea index (p < 0.001), and mixed apnea index (p < 0.001). CMAI% ≧25% emerged in 25% of patients after MMA (median CMAI%, 49.1%; 35.9-63.8). Within the undeniable limitations of the study, it seems that the presence of CMAI% ≧25% should not be regarded as a contraindication for MMA in OSA patients.
Identifiants
pubmed: 35778235
pii: S1010-5182(22)00090-7
doi: 10.1016/j.jcms.2022.06.005
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
537-542Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Nico de Vries is a member of the Medical Advisory Board of Night Balance. He is also an investigator for Inspire, Nyxoah and Jazz Pharmaceutics, consultant to Philips and Olympus. The other authors declare they have no conflicts of interest.